CureVac N.V.: EPO Confirms Validity of CureVac's Patent - Range Breakout in Preparation!
Reading Time: 2 minutes
The European Patent Office (EPO) confirmed on May 15, 2025, the validity of the CureVac patent EP 4 023 755 B1 in modified form. The opposition filed against this patent by BioNTech SE, Pfizer Inc., and other parties in December 2023 was largely rejected. Earlier in March 2025, the EPO also confirmed the validity of another CureVac patent, EP 3 708 668 B1, in modified form. CureVac views the EPO's decisions as a confirmation of its own research and development efforts in the field of mRNA technology. The two patents mentioned relate to the...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
